Why the study?
Inadequate antiplatelet effects can cause substantial morbidity and mortality in acute coronary syndrome and PCI, highlighting the need to review cangrelor's pharmacology, clinical profile, and role.
Does cangrelor reduce periprocedural complications in patients with acute coronary syndrome undergoing PCI compared to clopidogrel?
Does cangrelor reduce periprocedural complications in patients with acute coronary syndrome undergoing PCI compared to clopidogrel?
Cangrelor is a potent, rapid-onset intravenous P2Y12 inhibitor that reduces periprocedural complications during PCI in patients not previously treated with a P2Y12 inhibitor.
Supports cangrelor consideration in P2Y12-naive ACS PCI; leaves open head-to-head trials versus modern oral agents.
Inadequate antiplatelet effects can result in substantial morbidity and mortality in patients with acute coronary syndrome and percutaneous coronary intervention (PCI). Cangrelor is a rapid onset and potent intravenous P2Y12 inhibitor that has been shown in large randomized controlled trials to reduce periprocedural complications for PCI compared with clopidogrel, the most commonly used P2Y12 inhibitor. Cangrelor should be considered in the setting of PCI to reduce the risk of periprocedural complications such as myocardial infarction, repeat coronary revascularization and stent thrombosis in patients not yet treated with another P2Y12 inhibitor or glycoprotein IIb/IIIa inhibitor. In this review, the importance of adequate P2Y12 inhibition, cangrelor's pharmacology and clinical profiles, and future directions for the cangrelor are discussed.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: